View our masking and visitation guidelines based on current rates of respiratory illnesses in the community.

Ben Towne Center for Childhood Cancer Research
Back to... ➝
Donate Now
DIPG Research Program Menu
Back to... ➝
Donate Now

Publications

Dr. Vitanza has authored dozens of research papers, including the selected publications listed below. View a complete list of his publications on PubMed.

Selected Publications

  • Vitanza NA, Biery MC, Myers C, Ferguson E, Zheng Y, Girard EJ, Przystal JM, Park G, Noll A, Pakiam F, Winter CA, Morris SM, Sarthy J, Cole BL, Leary SES, Crane C, Lieberman NAP, Mueller S, Nazarian J, Gottardo R, Brusniak MY, Mhyre AJ, Olson JM. Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models. 33130903. Neuro Oncol. 2020 Nov 1. Online ahead of print.

  • Quon JL, Bala W, Chen LC, Wright J, Kim LH, Han M, Shpanskaya K , Lee EH, Tong E , Iv M , Seekins J, Lungren MP, Braun KRM, Poussaint TY, Laughlin S, Taylor MD, Lober RM, Vogel H, G Fisher P, Grant GA, Ramaswamy V, Vitanza NA, Ho CY, Edwards MSB, Cheshier SH, Yeom KW, Deep learning for pediatric posterior fossa tumor detection and classification: a multi-institutional study. 32816765. AJNR Am J Neuroradiol. 2020 Sep;41(9):1718-1725. Epub 2020 Aug 13.

  • Crotty EE, Leary SES, Geyer JR, Olson JM, Millard NE, Sato AA, Ermoian RP, Cole BL, Lockwood CM, Paulson VA, Browd SR, Ellenbogen RG, Hauptman JS, Lee A, Ojemann JG, Vitanza NA. Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience. 32556862. J Neurooncol. 2020 Jul; 148(3):607-617. Epub 2020 Jun 16.

  • Vitanza NA, Khalatbari H, Sarthy J, Ojemann JG, Browd SR, Ermoian RP, Lockwood C, Cole BL, Leary SES. Response to MEK inhibition in two cases of NF1 mutated diffuse midline glioma, H3 K27M-mutant. J Appl Lab Med. 2020 Aug 30:jfaa086. doi: 10.1093/jalm/jfaa086.

  • Ravanpay AC, Gust J, Johnson AJ, Berger C, Rolczynski LS, Cecchini M, Chang CA, Hoglund VJ, Mukherjee R, Vitanza NA, Orentas RJ, Jensen MC. EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma. Oncotarget. 2019 Dec 17; 10(66):7080-7095.

  • Lin GL, Wilsom, KM, Ceribelli M, Stanton BZ, Woo PJ, Kreimer S, Qin EY, Zhang X, Lennon J, Nagaraja S, Morris PJ, Quezada M, Gillespie SM, Duveau DY, Michalowski AM, Shinn M, Guha R, Ferrer M, Klumpp-Thomas C, Michael S, McKnight C, Minhas P, Itkin Z, Raabe EH, Chen L, Ghanem, Geraghty AC, Ni L, Andreasson K, Vitanza NA, Warren K, Thomas C, Monje M. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Sci. Transl. Med. 2019 Nov 20; 11(519).

  • Vitanza NA, Monje M. Diffuse Intrinsic Pontine Glioma: from diagnosis to next-generation clinical trials. Curr Treatment Options Neurol. 2019 Jul 10;21(8):37.

  • Lieberman NAP, Vitanza NA, Crane CA, Immunotherapy for brain tumors: understanding early successes and limitations. 29322843 Expert Review of Neurotherapeutics, 2018 Jan. 11:1-9.

  • Nagaraja S, Vitanza NA, Woo PJ, Taylor KR, Liu F, Zhang L, Li M, Meng W, Ponnuswami A, Sun W, Ma J, Hulleman E, Swigut T, Wysocka J, Tang Y, Monje M, Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma. 28434841 Cancer Cell, 2017 May 8:31(5)635-652.

Book Chapters

  • Vitanza NA, Campen CJ, Fisher PG
    Epidemiology of Pediatric CNS Tumors, Brain Tumors in Children, 2018

  • Vitanza NA, Fisher PG, Monje M.
    Diffuse Intrinsic Pontine Glioma, Swaiman's Pediatric Neurology: Principles and Practice 6th Edition, 2017

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.